BIO CEO & Investor Conference 2002 Spotlights Industry Leaders

Washington, D.C. (February 5, 2002)- The Biotechnology Industry Organization (BIO) today announced the names of the biotechnology companies selected to present at its fourth annual CEO & Investor Conference. The event, "Investing in Biotechnology: The Value, The Risks, The Rewards," will be held February 20-22 at the Waldorf-Astoria in New York City.

Selected from across the United States, Canada, Europe and Australia by an advisory board of leading industry executives, these companies will have the opportunity to share their advances in drug discovery to potential investors and partners. A complete list of presenting companies follows, and more information can be found at

“BIO is pleased to work with leading investors and visionary executives to create a forum for these groups to meet, exchange information and conduct business,” said Morrie Ruffin, BIO’s vice president for business development and emerging companies. “On the industry side, CEOs will get a chance to network and promote their companies to potential investors. Investors, analysts and reporters will get a closer look at the complex landscape of new ideas, technologies and business models they’ve been following, and a preview of what’s coming down the road.”

The conference will include 14 investor sessions, 9 CEO roundtables and 160 individual company presentations. In addition, 50 earlier-stage presenting companies will be showcased at the International Reception & Networking Exhibition. The investor sessions will discuss stem-cell therapies; autoimmune disease; cancer vaccines; proteomics; new technologies that could break the barriers to conceiving and developing drugs; the Festo patent ruling; heart disease drugs; anti-infectives; and how the "discovery" role in biotech has partly shifted to chemistry. The interactive roundtables will discuss consolidation in the industry, big pharma's view of biotechnology, protecting intellectual property and other topics.

CEO & Investor Conference 2002 sponsors include AstraZeneca; Ladenburg Thalmann & Co., Inc.: Adams, Harkness & Hill, Inc.; Fortis Bank; J.P. Morgan H&Q; Lazard; Lehman Brothers; PricewaterhouseCoopers, LLP; Thomas Weisel Partners, LLC; CIBC World Markets Corp.; Ferghana Partners, Inc.; Kenyon & Kenyon; Legg Mason Wood Walker, Inc.; Morrison & Foerster, LLP; Pacific Growth Equities, Inc.; Punk, Ziegel & Company; Robertson Stephens, Inc.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Hogan & Hartson, LLP; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, PC; The Nasdaq Stock Market, Inc.; Palmer & Dodge, LLP; Ropes & Gray; UBS Warburg; Accenture;
New York City Economic Development Corporation; EMC Corporation; Friedman, Billings, Ramsey Group, Inc.; GATX Ventures, Investissement Quebec; L.E.K. Consulting, LLC; Ronald Trahan Associates, Inc.; ShawPittman, LLP; Asset Alternatives; BioPeople Magazine; and FireRed.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit our Web site,

BIO CEO and Investor Conference 2002 Presenting Companies

3 - Dimensional Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc.
Acambis plc
Acorda Therapeutics Inc.
Acrux Limited
Active Pass Pharmaceuticals, Inc.
Advancis Pharmaceutical Corporation
AEterna Laboratories Inc.
AGY Therapeutics, Inc.
Albany Molecular Research, Inc.
Alizyme plc
Alkermes, Inc.
Alliance Pharmaceutical Corp.
Allos Therapeutics, Inc.
Alteon Inc.
Altus Biologics Inc.
amaxa GmbH
Anadys Pharmaceuticals, Inc.
AnalytiCon Discovery GmbH
Angiogene Inc
AnorMED Inc.
Antigenics Inc.
Applied Molecular Evolution, Inc.
Aradigm Corporation
Ardais Corporation
Ardana Bioscience Ltd
Arena Pharmaceuticals Inc.
Argonaut Technologies U.S.
ArQule, Inc.
Array BioPharma Inc.
Artecel Sciences, Inc.
Astex Technology Ltd
AtheroGenics, Inc.
Athersys, Inc.
Autogen Limited
AVANT Immunotherapeutics, Inc.
Axonyx Inc.
Battelle Pulmonary Therapeutics
Bavarian Nordic A/S
Bernina Biosystems GmbH
Biocom International Limited
BioMarin Pharmaceutical Inc.
BioMicro Systems Inc.
Biomira Inc.
BioTransplant Incorporated
BioVex Ltd
BTG plc
CancerVax Corporation
Caprion Phamaceuticals Inc.
Celgene Corporation
Cell Genesys, Inc.
Cell Therapeutics, Inc
Cellegy Pharmaceuticals Inc.
ChemGenex Therapeutics, Inc.
ChemoCentryx, Inc.
Cogent Neuroscience, Inc.
Coley Pharmaceutical Group
Collateral Therapeutics, Inc.
Connetics Corporation
Cortex Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
CuraGen Corporation
Curis, Inc.
Cytogen Corporation
Cytokinetics, Inc.
Cytovax Biotechnologies Inc.
Deltagen, Inc.
Dendreon Corporation
DepoMed, Inc.
diaDexus, Inc.
Digital Gene Technologies, Inc.
Discovery Laboratories, Inc.
Diversa Corporation
DOR BioPharma, Inc.
Dyax Corp.
Entomed S.A.
EntreMed, Inc.
Epimmune Inc.
EPIX Medical, Inc.
ES Cell International Pte Ltd
Esperion Therapeutics
Evacyte Corporation
Exelixis, Inc.
Forbes Medi-Tech Inc.
Genaera Corporation
Genaissance Pharmaceuticals, Inc.
GeneFormatics Incorporated
Genencor International, Inc.
Genmab A/S
Genome Therapeutics Corporation
Genta Incorporated
Genteric, Inc.
GenVec, Inc.
Genzyme Biosurgery
Genzyme General
Genzyme Molecular Oncology
Genzyme Transgenics Corporation
Geron Corporation
GlaxoSmithKline, Inc.
GPC Biotech AG
Guilford Pharmaceuticals Inc.
Hollis-Eden Pharmaceuticals, Inc.
Human Genome Sciences, Inc.
Hyseq Inc.
ICOS Corporation
Idun Pharmaceuticals, Inc.
ILEX Oncology, Inc.
ImClone Sytems Incorporated
ImmunoGen, Inc.
Immunomedics, Inc.
Immusol Incorporated
Inflazyme Pharmaceuticals Ltd.
Ingenium Pharmaceuticals AG
Inhale Therapeutic Systems, Inc.
Innogenetics NV
Insmed Incorporated
Inspire Pharmaceuticals, Inc.
InterMune Pharmaceuticals, Inc.
Introgen Therapeutics, Inc.
Isis Pharmaceutcials, Inc.
Kinetek Pharmaceuticals, Inc.
Kosan Biosciences, Inc.
KS Biomedix Holdings Plc
La Jolla Pharmaceutical Company
Lexicon Genetics Incorporated
Ligand Pharmaceuticals Incorporated
LION bioscience AG
MaxCyte, Inc.
Maxim Pharmaceuticals, Inc.
Maxygen, Inc.
Medarex, Inc.
MediGene AG
Metabolex, Inc.
Metagen GmbH
Millennium Pharmaceuticals, Inc.
Mojave Therapeutics, Inc.
MorphoSys AG
Narhex Life Sciences Ltd.
NeoPharm, Inc.
NeoRx Corporation
Neose Technologies, Inc.
Neurobiological Technologies, Inc.
Neurochem Inc.
Neurogen Corporation
Neurotech S.A.
Nobex Corporation
Novirio Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Onyx Pharmaceutcials, Inc.
OraPharma, Inc.
Orchid BioSciences, Inc.
OSI Pharmaceuticals, Inc.
Paradigm Genetics, Inc.
Peptor Ltd.
Pharmacopeia, Inc.
Pharmos Corporation
Phylos, Inc.
Physiome Sciences, Inc.
Pieris Proteolab AG
Prescient NeuroPharma Inc.
ProdiGene, Inc.
Progenics Pharmaceuticals, Inc.
Protein Sciences Corporation
PS Pharmaceuticals, Inc.
Psychiatric Genomics, Inc.
PTC Therapeutics, Inc.
Raven biotechnologies, inc.
Regeneron Pharmaceuticals, Inc.
Ribozyme Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc.
Sangamo BioSciences, Inc.
Scimagix, Inc.
Starpharma Pooled Development Limited
Stressgen Biotechnologies Corporation
Structural Bioinformatics Inc.
Structural GenomiX, Inc.
Surface Logix, Inc.
Target Discovery, Inc.
Targeted Genetics Corporation
Telik, Inc.
Texas Biotechnology Corporation
Tripos Inc.
Tularik Inc.
U.S. Genomics, Inc.
Valentis, Inc.
Variagenics, Inc.
Vasogen Inc.
Versicor, Inc.
Vertex Pharmaceuticals Incorporated
Viragen, Inc.
Virax Holdings Limited
Viscum AG
Wilex AG
Xenon Genetics Inc.
XTL Biopharmaceuticals Ltd.
YM BioSciences Inc.
Zapaq, Inc.
ZymoGenetics, Inc.

# # #